Rice Hall James & Associates LLC Has $3.14 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Rice Hall James & Associates LLC increased its position in Omnicell, Inc. (NASDAQ:OMCL) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,595 shares of the company’s stock after buying an additional 8,144 shares during the period. Rice Hall James & Associates LLC owned 0.15% of Omnicell worth $3,143,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Van ECK Associates Corp lifted its position in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after acquiring an additional 315 shares in the last quarter. KBC Group NV lifted its position in Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after acquiring an additional 778 shares in the last quarter. 1620 Investment Advisors Inc. lifted its position in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after acquiring an additional 1,542 shares in the last quarter. CIBC Asset Management Inc bought a new position in Omnicell in the 4th quarter valued at about $201,000. Finally, Summit Global Investments bought a new position in Omnicell in the 3rd quarter valued at about $221,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.64% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

OMCL has been the topic of several recent research reports. Benchmark reaffirmed a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Bank of America dropped their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. JPMorgan Chase & Co. lifted their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Barclays lifted their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, Craig Hallum lifted their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $52.33.

Omnicell Trading Up 0.9 %

NASDAQ:OMCL opened at $39.97 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.85 billion, a PE ratio of 148.04, a price-to-earnings-growth ratio of 7.52 and a beta of 0.78. The firm’s 50 day moving average is $43.49 and its 200 day moving average is $43.90. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.